FDA Places Hold on BioInvent’s Phase 2 Trial for Multiple Myeloma Therapy
The U.S. Food and Drug Administration (FDA) has verbally notified BioInvent International that it’s placing a full clinical hold on the company’s Phase 2 trial evaluating…
News
Karyopharm to Present Updated Clinical Data of Selinexor in Multiple Myeloma Patients
Karyopharm Therapeutics is set to present novel clinical data on its lead product candidate selinexor, an oral selective inhibitor of nuclear export compound that…
MorphoSys to Present Proprietary Hemato-Oncological Antibody Programs at ASH 2016
MorphoSys, the creator of HuCAL (Human Combinatorial Antibody Library), will give two oral and one poster presentation on the company’s proprietary antibody hemato-oncological programs, MOR208 and…
Genentech to Present Data From Multiple Clinical Trials on Myeloma and Other Blood Cancers
Genentech will present results on several approved or investigational therapies for blood cancers, including lymphoma and myeloma, in the upcoming 58th American Society…
Clinical Trial Will Assess Immunotherapy Combo in Multiple Myeloma Patients in 2017
Adaptimmune Therapeutics and Merck have agreed to begin a clinical trial next year assess the safety and efficacy of combining the anti-PD-1 inhibitor Keytruda…
Multiple Myeloma Patients Treated at Higher-volume Facilities Have Better Outcomes, Study Finds
Patients treated for multiple myeloma at facilities that see a higher number of multiple myeloma patients annually had better outcomes compared to patients who were treated at…
Longer Revlimid Maintenance after Stem Cell Transplant Prolongs Myeloma Patient Survival
Longer duration of maintenance therapy with Revlimid (lenalidomide) after autologous hematopoietic stem cell transplantation (HSCT) prolongs survival for multiple myeloma patients without increasing…
Experimental Myeloma Agent Shows Promise in Combination with Immunotherapies
Inhibiting a key protein in the tumor microenvironment using Noxxon’s experimental agent NOX-A12 may enhance the clinical activity of immunotherapies that boost T-cells or natural…
Xgeva Matches Standard of Care in Delaying Bone Lesions in Multiple Myeloma Patients, Amgen Reports
Amgen announced that its RANKL inhibitor, Xgeva (denosumab) met its primary endpoint in a  Phase 3 trial as a potential treatment for bone complications in…
Darzalex Combo Therapy Shows Promise in Relapsed or Refractory Multiple Myeloma Patients
A three-drug therapy combination consisting of Darzalex (daratumumab) with Revlimid (lenalidomide) and Decadron (dexamethasone) shows real potential in increasing survival in patients with…
